Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 2/20 | 0.39 |
| ▸ | JAK3 | P52333 | 2/20 | 0.39 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.38 |
| ▸ | MAP3K12 | Q12852 | 3/20 | 0.38 |
| ▸ | LTA4H | P09960 | 8/20 | 0.37 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.36 |
| ▸ | CCR4 | P51679 | 3/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.33 |
| ▸ | JAK1 | P23458 | 1/20 | 0.33 |
| ▸ | TYK2 | P29597 | 1/20 | 0.33 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4521856 | 0.90 | PIN1 (0.40) | BTKJAK3PIN1MAP3K12LTA4H | |
| SCHEMBL4524529 | 0.85 | JAK3 (0.34) | JAK3PIN1CCR4JAK2JAK1 | |
| SCHEMBL4521438 | 0.81 | IGF1R (0.40) | JAK3MAP3K12JAK2JAK1TYK2 | |
| SCHEMBL4513370 | 0.80 | ABCG2 (0.36) | LTA4HCCR4ABCG2 | |
| SCHEMBL4521519 | 0.79 | CCR4 (0.36) | CCR4ABCG2 | |
| SCHEMBL4515702 | 0.77 | PRKCQ (0.34) | JAK3CCR4JAK2TYK2ABCG2 | |
| SCHEMBL4515212 | 0.76 | CCR4 (0.35) | CCR4 | |
| SCHEMBL4535405 | 0.76 | AURKA (0.37) | BTKJAK3PIN1 | |
| SCHEMBL4529942 | 0.76 | PAK4 (0.39) | CCR4 | |
| SCHEMBL5314611 | 0.76 | PAK4 (0.34) | CCR4ABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1831216-A2 | HETEROAROMATIC DERIVATIVES USEFUL AS ANTICANCER AGENTS | Pfizer Products Inc. (US) | 2007-09-12 | — | — | EP | claimed |
| WO-2006067614-A2 | HETEROAROMATIC DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER PRODUCTS INC. (US) | 2006-06-29 | — | — | WO | claimed |
| US-20090281073-A1 | HETEROAROMATIC DERIVATIVES USEFUL AS ANTICANCER AGENTS | BHATTACHARYA SAMIT KUMAR | 2009-11-12 | — | — | US | disclosed |
| EP-1831216-A2 | HETEROAROMATIC DERIVATIVES USEFUL AS ANTICANCER AGENTS | Pfizer Products Inc. (US) | 2007-09-12 | — | — | EP | disclosed |
| WO-2006067614-A2 | HETEROAROMATIC DERIVATIVES USEFUL AS ANTICANCER AGENTS | PFIZER PRODUCTS INC. (US) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281073-A1 | HETEROAROMATIC DERIVATIVES USEFUL AS ANTICANCER AGENTS | CCNY, TP53, CCNE1 | BTK 3369/4885JAK3 2725/4885PIN1 1927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.